Fairness opinions › Acquirers
Laboratory Corporation of America: healthcare acquisitions with fairness opinions
3 public-company targets, 2012-2016, $6.2B combined enterprise value. The multiples Laboratory Corporation of America paid and the banker analyses behind each target board's recommendation.
Deals
3
Median EV / EBITDA paid
12.7x
Median EV / revenue paid
2.21x
| Announced | Target | Acquirer | Segment | EV | EV/EBITDA | EV/Rev | DCF rate | Fairness opinion |
|---|---|---|---|---|---|---|---|---|
| 2016-07-27 | Sequenom | Laboratory Corporation of America | Diagnostics / Life Sciences | $379M | — | 3.01x | 15.0%–17.0% | J.P. Morgan |
| 2014-11-03 | Covance | Laboratory Corporation of America | Pharmaceutical Services | $5.6B | 12.6x | 2.21x | 8.0%–10.0% | Goldman Sachs |
| 2012-06-04 | MEDTOX Scientific | Laboratory Corporation of America | Diagnostics / Life Sciences | $241M | 12.7x | 2.03x | 10.0%–12.0% | Lazard Middle Market |